Abstract:ID 93099 Poster Board 548 Background/Objective: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, whereas over 300 million individuals suffer from asthma worldwide. Cigarette smoking is recognized as the major risk factor in COPD and asthma patients who smoke often have poorly controlled disease. Glucocorticoids (GC) are the most effective anti-inflammatory drugs available. However, COPD and refractory severe asthma are frequently resistant to glucocorticoid therapy, thus posing an unmet need for better therapies. Although immune cells have been used to investigate glucocorticoid insensitivity (GCI), airway smooth muscle (ASM) cells have emerged as key contributors not only to airway hyperresponsiveness (AHR) but also to airway inflammation in patients with COPD and severe asthma. The objective of this study was to investigate effects of cigarette smoke exposure on glucocorticoid sensitivity of ASM cells. Hypothesis: Cigarette smoking exposure renders ASM cells insensitive to glucocorticoid transactivation. Methods: Primary human ASM cells derived from healthy controls and asthma patients were treated with various concentrations of cigarette smoking extract (CSE) for 24 h or two weeks. GC transactivation was measured using a Glucocorticoid Response Element (GRE)-driven luciferase reporter assay and measuring GC-inducible gene expression by qRT-PCR. Single-cell RNA sequencing was performed to identify differentially expressed genes (DEGs) in HASM cells and confirmed by qRT-PCR. Twenty normal nonsmoking subjects were enrolled as controls, with screening FEV1> 80% predicted. Forty current smokers were also enrolled, divided into subjects who demonstrated AHR, with a positive methacholine challenge (n = 20) versus those without AHR (n = 20). DEGs expression from peripheral blood mononuclear cells (PBMC) in chronic smokers, with and without AHR were determined by western blot assays. Data are presented as the mean ± SEM. P <0.05 is considered to be statistically significant. Results: CSE treatment for 24 h impaired GRE activation and the GC induction of several anti-inflammatory genes in multiple HASM cell lines in a dose-dependent manner with 70% reduction in 5% CSE-treated HASM cells. Chronic treatment with 2.5% CSE caused transcriptomic changes in HASM cells including Regulator of G Protein Signaling 2 (RGS2), a key regulator of ASM hypercontraction and AHR in asthma. Importantly, the GC dexamethasone enhanced β2-agonist albuterol-induced RGS2 expression in HASM cells, which was also impaired in CSE-treated HASM cells. In addition, RGS2 protein expression was significantly reduced in PBMC from chronic smokers without AHR, and to a greater degree in smokers with AHR, versus non-smokers. Conclusions: Our results indicate that CSE exposure not only profoundly impairs GC transactivation but also abolished dexamethasone and β2-agonist-induced RGS2 protein expression in HASM cells. Since RGS2 upregulation is a genomic mechanism of β2 - agonist-induced bronchoprotection that is enhanced by GC, our study suggests ASM as an important target for glucocorticoid therapy and may contribute to cigarette smoking-related GC insensitivity seen in patients with COPD and severe asthma.

Glucocorticoids Regulate Tight Junction Permeability of Lung Epithelia by Modulating Claudin 8

Differential Effects of Low- and High-Dose Glucocorticoids on the Innate Immunity of Corneal Epithelium in Vitro

Glucocorticoids Distinctively Modulate the CFTR Channel with Possible Implications in Lung Development and Transition into Extrauterine Life

Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37

Glucocorticoids inhibit the innate immune system of human corneal fibroblast through their suppression of toll-like receptors.

Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells

Extra-adrenal glucocorticoid synthesis at epithelial barriers

Claudin targeting as an effective tool for directed barrier modulation of the viable epidermis

Knockout mice reveal key roles for claudin 18 in alveolar barrier properties and fluid homeostasis

Interplay between nuclear factor-κB, p38 MAPK, and glucocorticoid receptor signaling synergistically induces functional TLR2 in lung epithelial cells

Glucocorticoid Dose Dependency on Gene Expression in Vocal Fold Fibroblasts and Macrophages

Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis.

Tight Junctions, the Epithelial Barrier, and Toll-like Receptor-4 During Lung Injury

Dexamethasone rescues TGF-β1-mediated β2-adrenergic receptor dysfunction and attenuates phosphodiesterase 4D expression in human airway smooth muscle cells

Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation

Glucocorticoid Alleviates Mechanical Stress-Induced Airway Inflammation and Remodeling in COPD via Transient Receptor Potential Canonical 1 Channel

GLCCI1 Deficiency Induces Glucocorticoid Resistance Via the Competitive Binding of IRF1:GRIP1 and IRF3:GRIP1 in Asthma

Glucocorticoids Elevate Pseudomonas Aeruginosa Binding to Airway Epithelium by Upregulating Syndecan-1 Expression

Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases

Cigarette Smoke Exposure and Glucocorticoid Insensitivity of Airway Smooth Muscle Cells

Modulation of Lung Epithelial Cell Function Using Conditional and Inducible Transgenic Approaches